Pay in 4 interest-free payments of $7.17 Learn more
:format(webp))
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Based on Obesity Canada guidelines and clinical trials (typically over ~1 year): Saxenda: ~58% total body weight loss Wegovy: ~1015% total body weight loss Tirzepatide: ~1520% (or more) total body weight loss weight loss is gradual and occurs over several months, with the most significant changes seen after reaching the full therapeutic dose results vary depending on adherence, lifestyle factors, and individual response 7
This ultra-low starting dose is designed for patients with high sensitivity to GLP-1 medications, those who have experienced severe side effects on semaglutide or other GLP-1 medications , or patients who want the most gradual possible introduction
This change helps it keep working for a longer time, which means it can keep talking to the body's cells in a consistent way
effect more stable Time point Week 12 What the trials reported Around half of the 24-week weight loss usually observed by this point Time point Week 24 What the trials reported Phase 2 primary endpoint: about 10-11% body weight loss at 0.5 mg
It digests easily and rarely triggers the nausea or bloating that fattier proteins can cause
